ASCO GU 2021: Final Results from ACIS, a Randomized, Placebo-Controlled Double-Blind Phase 3 Study of Apalutamide and Abiraterone Acetate plus Prednisone (AAP) Versus AAP in Patients with Chemo-Naive Metastatic Castration-Resistant Prostate Cancer

(UroToday.com) Metastatic castration resistant prostate cancer (mCRPC) continues to be driven by androgen signaling, but this patient population has heterogeneous responses to second-generation androgen pathway inhibitors. Apalutamide, an androgen receptor antagonist, and abiraterone acetate, and androgen synthesis inhibitor, have somewhat distinct mechanisms of action and efficacy in mCRPC. The ACIS trial (NCT02257736) was designed to study is the combination of these two therapies, termed androgen annihilation, as first-line therapy in mCRPC.


The schema of the study is shown below. In total, 982 patients were randomized in a 1:1 fashion to either the combination of apalutamide and abiraterone or abiraterone plus placebo. All patients were also on androgen deprivation therapy. The primary endpoint of the study was radiographic progression free survival. In this presentation, Dr. Dana Rathkopf presented final results from a data cutoff of September 2020.

ASCO_GU_NCT02257736.png

Regarding patient characteristics, baseline clinical characteristics between the two study arms were similar, including comparable rates of bone as well as visceral liver and lung metastases.

ASCO_GU_ACIS_trial.png

The overall data from this trial are summarized below in the table. Notably, the trial met its primary endpoint of rPFS benefit with androgen annihilation, prolonging rPFS from 16.6 months to 22.6 months (HR 0.69, p < 0.0001). However, after 54.8 months of median follow-up at the September 2020 data cutoff, overall survival was numerically higher but not statistically significantly higher with androgen annihilation (36.2 months versus 33.7 months, p = 0.498).

ASCO_GU_Rathkopf.png

ASCO_GU_visceral_metastases.png

Across all pre-specified subgroups, including the presence of visceral metastases and age >= 75 years, there was a trend towards benefit from combination androgen annihilation.

ASCO_GU_androgen_annihilation.png

Other secondary and exploratory endpoints, including time to initiation of cytotoxic chemotherapy, pain progression, chronic opioid use, and second progression free survival were similar between groups. Two-third of patients on trial were able to go on and receive another life prolonging therapy (70% chemotherapy, ~20% another hormonal therapy). Finally, more patients experienced a decline in PSA of greater than 50% with androgen annihilation, as shown in the waterfall plot and table below.

ASCO_GU_decline_in_PSA.png

In an exploratory analysis of biomarkers of response, tumors classified as luminal by the PAM50 signature score, or those having high AR activity expression signatures trended towards improved rPFS and overall survival with androgen annihilation.

ASCO_GU_PAM50.png

With regards to safety, the profile of androgen annihilation was as would be expected from the cumulative effects of both drugs, with no new safety signals. Based on FACT-P score, QoL was similar between each group.

ASCO_GU_FACT-P_score.png

ASCO_GU_QoL.png

Dr. Rathkopf concluded that the ACIS trial met its primary outcome of showing an rPFS benefit for abiraterone plus apalutamide as first line therapy in mCRPC, but the secondary endpoint of overall survival and others were similar between the treatment arms. While more treatment related adverse events were noted in the combination arm, the overall QoL as measured by FACT-P was similar between arms.

Presented by: Dana Rathkopf, MD, Medical Oncologist, Memorial Sloan-Kettering Cancer Center,

Written by: Alok Tewari, MD, PhD, Medical Oncologist at the Dana-Farber Cancer Institute, during the 2021 ASCO Genitourinary Cancers Symposium (ASCO GU), February 11th to 13th, 2021
email news signup